These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 28558966)

  • 21. Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease.
    Kester MI; Teunissen CE; Crimmins DL; Herries EM; Ladenson JH; Scheltens P; van der Flier WM; Morris JC; Holtzman DM; Fagan AM
    JAMA Neurol; 2015 Nov; 72(11):1275-80. PubMed ID: 26366630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Skin autofluorescence, reflecting accumulation of advanced glycation end products, and the risk of dementia in a population-based cohort.
    Mooldijk SS; Lu T; Waqas K; Chen J; Vernooij MW; Ikram MK; Zillikens MC; Ikram MA
    Sci Rep; 2024 Jan; 14(1):1256. PubMed ID: 38218902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perspective of Advanced Glycation End Products on Human Health.
    Lin JA; Wu CH; Yen GC
    J Agric Food Chem; 2018 Mar; 66(9):2065-2070. PubMed ID: 29421872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Skin autofluorescence as a measure of advanced glycation end products deposition is elevated in peripheral artery disease.
    de Vos LC; Noordzij MJ; Mulder DJ; Smit AJ; Lutgers HL; Dullaart RP; Kamphuisen PW; Zeebregts CJ; Lefrandt JD
    Arterioscler Thromb Vasc Biol; 2013 Jan; 33(1):131-8. PubMed ID: 23139292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
    Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between blood pressure and Alzheimer disease measured up to 27 years prior to diagnosis: the HUNT Study.
    Gabin JM; Tambs K; Saltvedt I; Sund E; Holmen J
    Alzheimers Res Ther; 2017 May; 9(1):37. PubMed ID: 28569205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myoclonus, seizures, and paratonia in Alzheimer disease.
    Risse SC; Lampe TH; Bird TD; Nochlin D; Sumi SM; Keenan T; Cubberley L; Peskind E; Raskind MA
    Alzheimer Dis Assoc Disord; 1990; 4(4):217-25. PubMed ID: 2264979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of peripheral neuropathy with circulating advanced glycation end products, soluble receptor for advanced glycation end products and other risk factors in patients with type 2 diabetes.
    Aubert CE; Michel PL; Gillery P; Jaisson S; Fonfrede M; Morel F; Hartemann A; Bourron O
    Diabetes Metab Res Rev; 2014 Nov; 30(8):679-85. PubMed ID: 24449227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paratonia, Gegenhalten and psychomotor hypertonia Back to the roots.
    Foucher JR; Dormegny-Jeanjean LC; Bartsch AJ; Humbert I; de Billy CC; Obrecht A; Mainberger O; Clauss JME; Waddington JL; Wolf RC; Hirjak D; Morra C; Ungvari G; Schorr B; Berna F; Shorter E
    Schizophr Res; 2024 Jan; 263():35-44. PubMed ID: 36155159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucagon-like peptide-1 analogue liraglutide ameliorates atherogenesis via inhibiting advanced glycation end product-induced receptor for advanced glycosylation end product expression in apolipoprotein-E deficient mice.
    Li P; Tang Z; Wang L; Feng B
    Mol Med Rep; 2017 Sep; 16(3):3421-3426. PubMed ID: 28713911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia.
    Emanuele E; D'Angelo A; Tomaino C; Binetti G; Ghidoni R; Politi P; Bernardi L; Maletta R; Bruni AC; Geroldi D
    Arch Neurol; 2005 Nov; 62(11):1734-6. PubMed ID: 16286548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
    Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
    JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advanced Glycation End Products Are Associated With Physical Activity and Physical Functioning in the Older Population.
    Drenth H; Zuidema SU; Krijnen WP; Bautmans I; Smit AJ; van der Schans C; Hobbelen H
    J Gerontol A Biol Sci Med Sci; 2018 Oct; 73(11):1545-1551. PubMed ID: 29718128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease.
    Sanz C; Andrieu S; Sinclair A; Hanaire H; Vellas B;
    Neurology; 2009 Oct; 73(17):1359-66. PubMed ID: 19858457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Coexisting cerebral infarction in Alzheimer's disease is associated with fast dementia progression: applying the National Institute for Neurological Disorders and Stroke/Association Internationale pour la Recherche et l'Enseignement en Neurosciences Neuroimaging Criteria in Alzheimer's Disease with Concomitant Cerebral Infarction.
    Sheng B; Cheng LF; Law CB; Li HL; Yeung KM; Lau KK
    J Am Geriatr Soc; 2007 Jun; 55(6):918-22. PubMed ID: 17537094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Skin autofluorescence associates with vascular calcification in chronic kidney disease.
    Wang AY; Wong CK; Yau YY; Wong S; Chan IH; Lam CW
    Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1784-90. PubMed ID: 24876353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognosis of an abnormal one-leg balance in community-dwelling patients with Alzheimer's disease: a 2-year prospective study in 686 patients of the REAL.FR study.
    Sourdet S; van Kan GA; Soto ME; Houles M; Cantet C; Nourhashemi F; Vellas B; Pahor M; Rolland Y
    J Am Med Dir Assoc; 2012 May; 13(4):407.e1-6. PubMed ID: 22227074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Electromyographic Patterns of Paratonia in Normal Subjects and in Patients with Mild Cognitive Impairment or Alzheimer's Disease.
    Marinelli L; Trompetto C; Puce L; Monacelli F; Mori L; Serrati C; Fattapposta F; Ghilardi MF; Currà A
    J Alzheimers Dis; 2022; 87(3):1065-1077. PubMed ID: 35431243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment.
    Jessen F; Wiese B; Bachmann C; Eifflaender-Gorfer S; Haller F; Kölsch H; Luck T; Mösch E; van den Bussche H; Wagner M; Wollny A; Zimmermann T; Pentzek M; Riedel-Heller SG; Romberg HP; Weyerer S; Kaduszkiewicz H; Maier W; Bickel H;
    Arch Gen Psychiatry; 2010 Apr; 67(4):414-22. PubMed ID: 20368517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of Pain in Nursing Home Residents: The Role of Dementia Stage and Dementia Subtypes.
    van Kooten J; Smalbrugge M; van der Wouden JC; Stek ML; Hertogh CMPM
    J Am Med Dir Assoc; 2017 Jun; 18(6):522-527. PubMed ID: 28236607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.